Newsfeeds - Spark Newswire

4 minute read

Regulus Therapeutics To Present Additional Data From Autosomal Dominant Polycystic Kidney Disease Program At PKD Connect 2021 At 2-3 p.m. CDT.

Today, 11:29 AM

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today

RGLS

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 11:29 AM

Gainers

ADMP

5 minute read

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs

By Shanthi Rexaline

Today, 11:29 AM

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

ABBV

2 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 11:29 AM

ACRS

1 minute read

Uncategorized

Regulus’s Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis

By Vandana Singh

Today, 11:29 AM

Regulus Therapeutics Inc (NASDAQ: RGLS) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b…

RGLS

2 minute read

Uncategorized

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 11:29 AM

Gainers

ADXS

14 minute read

Uncategorized

Earnings Scheduled For May 13, 2021

By Benzinga Insights

Today, 11:29 AM

Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.

AACG

6 minute read

Uncategorized

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

By Shanthi Rexaline

Today, 11:29 AM

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.

ABCL